The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Warner, Christina V ^a   Syc, Stephanie B ^a   Stankiewicz, Aleksandra M ^a   Hiremath, Girish ^a   Farrell, Sheena K ^a   Crainiceanu, Ciprian M ^b   Conger, Amy ^c   Frohman, Teresa C ^c   Bisker, Esther R ^d   Balcer, Laura J ^d   Frohman, Elliot M ^c   Calabresi, Peter A ^a   Saidha, Shiv ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINA MACULA LUTEA; RETINA NERVE CELL; RETINAL NERVE FIBER LAYER; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; THICKNESS; CLINICAL TRIAL; INSTRUMENTATION; NERVE FIBER; PATHOLOGY; RETINA;

ADULT; FEMALE; HUMANS; MACULA LUTEA; MALE; MULTIPLE SCLEROSIS; NERVE FIBERS; RETINA; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 80051635035     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022947     Document Type: Article

References (69)

1. van Waesberghe JH, Kamphorst W, De Groot CJ, van Walderveen MA, Castelijns JA, et al. (1999) Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. Ann Neurol 46 (5): 747-754.
2. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, et al. (2001) Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 58 (1): 65-70.
3. Minneboo A, Uitdehaag BM, Jongen P, Vrenken H, Knol D, et al. (2009) Association between MRI parameters and the MS severity scale: A 12 year follow-up study. Mult Scler 15 (5): 632-637.
4. Calabrese M, De Stefano N, Atzori M, Bernardi V, Mattisi I, et al. (2007) Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 64 (10): 1416-1422.
5. Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, et al. (2009) Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 66 (9): 1144-1150.
6. Kornek B, Lassmann H, (1999) Axonal pathology in multiple sclerosis. A historical note. Brain Pathol 9 pp. 651-656.
7. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, et al. (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157 (1): 267-276.
8. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, et al. (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338 (5): 278-285.
9. Bjartmar C, Trapp BD, (2001) Axonal and neuronal degeneration in multiple sclerosis: Mechanisms and functional consequences. Curr Opin Neurol 14 (3): 271-278.
10. Dutta R, Trapp BD, (2007) Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 68 (22) Suppl 3: S22-31; discussion S43-54.
11. Rawes JA, Calabrese VP, Khan OA, DeVries GH, (1997) Antibodies to the axolemma-enriched fraction in the cerebrospinal fluid and serum of patients with multiple sclerosis and other neurological diseases. Mult Scler 3 (6): 363-369.
12. Shindler KS, Ventura E, Dutt M, Rostami A, (2008) Inflammatory demyelination induces axonal injury and retinal ganglion cell apoptosis in experimental optic neuritis. Exp Eye Res 87 (3): 208-213.
13. Madigan MC, Rao NS, Tenhula WN, Sadun AA, (1996) Preliminary morphometric study of tumor necrosis factor-alpha (TNF alpha)-induced rabbit optic neuropathy. Neurol Res 18 (3): 233-236.
14. Frohman EM, Fujimoto JG, Frohman TC, Calabresi PA, Cutter G, et al. (2008) Optical coherence tomography: A window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol 4 (12): 664-675.
15. Saidha S, Eckstein C, Ratchford JN, (2010) Optical coherence tomography as a marker of axonal damage in multiple sclerosis. CML- Multiple Sclerosis 2 (2): 33-43.
16. Hsu IJ, Sun CW, Lu CW, Yang CC, Chiang CP, et al. (2003) Resolution improvement with dispersion manipulation and a retrieval algorithm in optical coherence tomography. Appl Opt 42 (2): 227-234.
17. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, et al. (1991) Optical coherence tomography. Science 254 (5035): 1178-1181.
18. Parisi V, Manni G, Spadaro M, Colacino G, Restuccia R, et al. (1999) Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci 40 (11): 2520-2527.
19. Trip SA, Schlottmann PG, Jones SJ, Altmann DR, Garway-Heath DF, et al. (2005) Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 58 (3): 383-391.
20. Balcer LJ, (2006) Clinical practice. optic neuritis. N Engl J Med 354 (12): 1273-1280.
21. Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S, (2005) The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 4 (2): 111-121.
22. Toussaint D, Perier O, Verstappen A, Bervoets S, (1983) Clinicopathological study of the visual pathways, eyes, and cerebral hemispheres in 32 cases of disseminated sclerosis. J Clin Neuroophthalmol 3 (3): 211-220.
23. Ikuta F, Zimmerman HM, (1976) Distribution of plaques in seventy autopsy cases of multiple sclerosis in the united states. Neurology 26 (6 PT 2): 26-28.
24. Naismith RT, Xu J, Tutlam NT, Trinkaus K, Cross AH, et al. (2010) Radial diffusivity in remote optic neuritis discriminates visual outcomes. Neurology 74 (21): 1702-1710.
25. Burkholder BM, Osborne B, Loguidice MJ, Bisker E, Frohman TC, et al. (2009) Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol 66 (11): 1366-1372.
26. Fisher JB, Jacobs DA, Markowitz CE, Galetta SL, Volpe NJ, et al. (2006) Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113 (2): 324-332.
27. Costello F, Coupland S, Hodge W, Lorello GR, Koroluk J, et al. (2006) Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 59 (6): 963-969.
28. Pulicken M, Gordon-Lipkin E, Balcer LJ, Frohman E, Cutter G, et al. (2007) Optical coherence tomography and disease subtype in multiple sclerosis. Neurology 69 (22): 2085-2092.
29. Gordon-Lipkin E, Chodkowski B, Reich DS, Smith SA, Pulicken M, et al. (2007) Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 69 (16): 1603-1609.
30. Siger M, Dziegielewski K, Jasek L, Bieniek M, Nicpan A, et al. (2008) Optical coherence tomography in multiple sclerosis: Thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J Neurol 255 (10): 1555-1560.
31. Villoslada P, Sepulcre J, Toledo J, Bejarano B, (2008) Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 71 (21): 1747; author reply 1747-8.
32. Grazioli E, Zivadinov R, Weinstock-Guttman B, Lincoff N, Baier M, et al. (2008) Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci 268 (1-2): 12-17.
33. Perry VH, Lund RD, (1990) Evidence that the lamina cribrosa prevents intraretinal myelination of retinal ganglion cell axons. J Neurocytol 19 (2): 265-272.
34. Heckenlively AG Jr, eds. (1991) Principles and practices of clinical electrophysiology of vision Mosby Year Book Inc pp. 25-52.
35. Schuman JS, Pedut-Kloizman T, Pakter H, Wang N, Guedes V, et al. (2007) Optical coherence tomography and histologic measurements of nerve fiber layer thickness in normal and glaucomatous monkey eyes. Invest Ophthalmol Vis Sci 48 (8): 3645-3654.
36. Cettomai D, Pulicken M, Gordon-Lipkin E, Salter A, Frohman TC, et al. (2008) Reproducibility of optical coherence tomography in multiple sclerosis. Arch Neurol 65 (9): 1218-1222.
37. Syc SB, Warner CV, Hiremath GS, Farrell SK, Ratchford JN, et al. (2010) Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler 16 (7): 829-839.
38. Talman LS, Bisker ER, Sackel DJ, Long DA Jr, Galetta KM, et al. (2010) Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol 67 (6): 749-760.
39. Choma M, Sarunic M, Yang C, Izatt J, (2003) Sensitivity advantage of swept source and fourier domain optical coherence tomography. Opt Express 11 (18): 2183-2189.
40. de Boer JF, Cense B, Park BH, Pierce MC, Tearney GJ, et al. (2003) Improved signal-to-noise ratio in spectral-domain compared with time-domain optical coherence tomography. Opt Lett 28 (21): 2067-2069.
41. Wojtkowski M, Srinivasan V, Fujimoto JG, Ko T, Schuman JS, et al. (2005) Three-dimensional retinal imaging with high-speed ultrahigh-resolution optical coherence tomography. Ophthalmology 112 (10): 1734-1746.
42. Keane PA, Mand PS, Liakopoulos S, Walsh AC, Sadda SR, (2009) Accuracy of retinal thickness measurements obtained with cirrus optical coherence tomography. Br J Ophthalmol 93 (11): 1461-1467.
43. Menke MN, Dabov S, Sturm V, (2009) Comparison of three different optical coherence tomography models for total macular thickness measurements in healthy controls. Ophthalmologica 223 (6): 352-356.
44. Grover S, Murthy RK, Brar VS, Chalam KV, (2009) Comparison of retinal thickness in normal eyes using stratus and spectralis optical coherence tomography. Invest Ophthalmol Vis Sci.
45. Bock M, Brandt AU, Dorr J, Pfueller CF, Ohlraun S, et al. (2010) Time domain and spectral domain optical coherence tomography in multiple sclerosis: A comparative cross-sectional study. Mult Scler 16 (7): 893-896.
46. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol 58 (6): 840-846.
47. Lublin FD, Reingold SC, (1996) Defining the clinical course of multiple sclerosis: Results of an international survey. national multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology 46 (4): 907-911.
48. ETDRS Research Group. (1985) Early treatment diabetic retinopathy study research group. photocoagulation for diabetic macular edema. early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 103 (12): 1796-1806.
49. Altman DG, Bland JM, (1986) Comparison of methods of measuring blood pressure. J Epidemiol Community Health 40 (3): 274-277.
50. Bland JM, Altman DG, (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1 (8476): 307-310.
51. Filippi M, van Waesberghe JH, Horsfield MA, Bressi S, Gasperini C, et al. (1997) Interscanner variation in brain MRI lesion load measurements in MS: Implications for clinical trials. Neurology 49 (2): 371-377.
52. Filippi M, Rocca MA, Gasperini C, Sormani MP, Bastianello S, et al. (1999) Interscanner variation in brain MR lesion load measurements in multiple sclerosis using conventional spin-echo, rapid relaxation-enhanced, and fast-FLAIR sequences. AJNR Am J Neuroradiol 20 (1): 133-137.
53. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, et al. (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 371 (9630): 2085-2092.
54. Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M, et al. (2011) Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol 69 (1): 75-82.
55. Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, et al. (2010) Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci 292 (1-2): 28-35.
56. Knight OJ, Chang RT, Feuer WJ, Budenz DL, (2009) Comparison of retinal nerve fiber layer measurements using time domain and spectral domain optical coherent tomography. Ophthalmology 116 (7): 1271-1277.
57. Vizzeri G, Weinreb RN, Gonzalez-Garcia AO, Bowd C, Medeiros FA, et al. (2009) Agreement between spectral-domain and time-domain OCT for measuring RNFL thickness. Br J Ophthalmol 93 (6): 775-781.
58. Tan BB, Natividad M, Chua KC, Yip LW, (2011) Comparison of retinal nerve fiber layer measurement between 2 spectral domain OCT instruments. J Glaucoma doi:1097/IJG.0b013e3182071cdd.
59. Garcia-Martin E, Pueyo V, Pinilla I, Ara JR, Martin J, et al. (2011) Fourier-domain OCT in multiple sclerosis patients: Reproducibility and ability to detect retinal nerve fiber layer atrophy. Invest Ophthalmol Vis Sci 52 (7): 4124-4131.
60. Leite MT, Rao HL, Weinreb RN, Zangwill LM, Bowd C, et al. (2011) Agreement among spectral-domain optical coherence tomography instruments for assessing retinal nerve fiber layer thickness. Am J Ophthalmol 151 (1): 85-92.e1.
61. Pons ME, Garcia-Valenzuela E, (2005) Redefining the limit of the outer retina in optical coherence tomography scans. Ophthalmology 112 (6): 1079-1085.
62. Costa RA, Calucci D, Skaf M, Cardillo JA, Castro JC, et al. (2004) Optical coherence tomography 3: Automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci 45 (7): 2399-2406.
63. Costa RA, Skaf M, Melo LA Jr, Calucci D, Cardillo JA, et al. (2006) Retinal assessment using optical coherence tomography. Prog Retin Eye Res 25 (3): 325-353.
64. Jeoung JW, Park KH, (2010) Comparison of cirrus OCT and stratus OCT on the ability to detect localized retinal nerve fiber layer defects in preperimetric glaucoma. Invest Ophthalmol Vis Sci 51 (2): 938-945.
65. Saidha S, Syc SB, Ibrahim MA, Eckstein C, Warner CV, et al. (2011) Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain 134 (Pt 2): 518-533.
66. Seibold LK, Mandava N, Kahook MY, (2010) Comparison of retinal nerve fiber layer thickness in normal eyes using time-domain and spectral-domain optical coherence tomography. Am J Ophthalmol 150 (6): 807-814.
67. Arthur SN, Smith SD, Wright MM, Grajewski AL, Wang Q, et al. (2011) Reproducibility and agreement in evaluating retinal nerve fibre layer thickness between stratus and spectralis OCT. Eye (Lond) 25 (2): 192-200.
68. Budenz DL, Fredette MJ, Feuer WJ, Anderson DR, (2008) Reproducibility of peripapillary retinal nerve fiber thickness measurements with stratus OCT in glaucomatous eyes. Ophthalmology 115 (4): 661-666.e4.
69. Langenegger SJ, Funk J, Toeteberg-Harms M, (2011) Reproducibility of retinal nerve fiber layer thickness measurements using the eye tracker and retest function of spectralis(R) SD-OCT in glaucomatous eyes and healthy controls. Invest Ophthalmol Vis Sci 52 (6): 3338-3344.